Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)

NCT00495625 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Liver Cancer

Interventions

DRUG: Sunitinib Malate

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]